Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Translate Bio Inc (TBIO) USD0.001

Sell:$13.42 Buy:$13.43 Change: $0.11 (0.83%)
Market closed |  Prices as at close on 27 October 2020 | Switch to live prices |
Change: $0.11 (0.83%)
Market closed |  Prices as at close on 27 October 2020 | Switch to live prices |
Change: $0.11 (0.83%)
Market closed |  Prices as at close on 27 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.

Contact details

29 Hartwell Ave
United States
+1 (617) 9457361

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$997.10 million
Shares in issue:
74.24 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Daniel Lynch
    Independent Chairman of the Board
  • Ronald Renaud
    President, Chief Executive Officer, Director
  • Michael Heartlein
    Founder, Executive Vice President
  • John Schroer
    Chief Financial Officer, Treasurer
  • Paul Burgess
    Chief Operating Officer, Chief Legal Officer
  • Paula Cloghessy
    Chief Human Resource Officer
  • Frank DeRosa
    Chief Technology Officer
  • Richard Wooster
    Chief Scientific Officer
  • Ann Barbier
    Chief Medical Officer
  • Brian Fenton
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.